Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this Phase I/II clinical trial is to assess the safety and maximum tolerated training time of a self-administered computerized cognitive training (CCT) in individuals with cognitive dysfunction as a consequence of COVID-19 infection.
A Phase I/II protocol is designed to determine the safety of a Computerized Cognitive Training (CCT) aimed at ameliorating the cognitive dysfunction often observed in persons with post-acute sequelae of COVID-19 (PASC). The Phase I/II trial also aims at establishing the maximum tolerated training time per session of the CCT and to explore the feasibility of such intervention. In Phase I, through a 3+3 design, a dose-escalation trial will be set. Participants will be tested across subsequent training blocks of 15 minutes each, reporting on the experienced fatigue or adverse effects after every block. The safe training dose will be set to a block before extreme fatigue or a notable adverse effect has been reported by two or more participants. Once a safety training time has been established, a group of participants will engage in a 15-day training effectiveness assessment. After an initial thorough pre-test assessment, the intervention protocol will start. An evaluation day and a training day will be interspersed so that participants will complete a total of 8 training sessions (days 1, 3, 5, 7, 9, 11, 13 and 15). After the final day of intervention, a post-test assessment session will be carried out.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Computerized Cognitive Training | Experimental | Individuals enrolled in Phase I and II will complete a Computerized Cognitive Training (CCT) based on an intervention with 15 different cognitive tasks in the form of games aimed at enhancing memory, attention, reasoning, perception and coordination skills. The CCT will be implemented in an app designed by CogniFit (CogniFit Inc., San Francisco, USA) to be used in tablets or mobile phones. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| CCT Long COVID | Behavioral | A 15-day training protocol in which every 48 hours participants' complete a series of different cognitive tasks in the form of games selected among a pool of 12 games from CogniFit (CogniFit Inc., San Francisco, USA) whose difficulty level is tailored to each individual by the a patented Individualized Training Systemâ„¢ (ITS) software that automatically chooses the activities and difficulty levels for each person in every session. |
| Measure | Description | Time Frame |
|---|---|---|
| Fatigue Level Questionnaire | Fatigue questionnaire adapted from the Brief Fatigue Inventory (Mendoza et al., 1999) | In Phase I, after each iteration of a 15-minute training. |
| Fatigue Level Questionnaire | Fatigue questionnaire adapted from the Brief Fatigue Inventory (Mendoza et al., 1999) | In Phase II, on even days (rest days of the intervention protocol). |
| Safety Level Questionnaire | Safety questionnaire aimed at exploring the existence of side effects and/or adverse events. | In Phase I, after each iteration of a 15-minute training. |
| Safety Level Questionnaire | Safety questionnaire aimed at exploring the existence of side effects and/or adverse events. | In Phase II, on even days (rest days of the intervention protocol). |
| Classification of side effect or adverse events | Interview adapted from the Patient-Reported Adverse Drug Event Questionnaire (de Vries et al., 2013). | In Phase I, after each iteration of a 15-minute training, only in case side effects or adverse events have been reported in the Safety Questionnaire. |
| Classification of side effect or adverse events | Interview adapted from the Patient-Reported Adverse Drug Event Questionnaire (de Vries et al., 2013). | In Phase II, on even days (rest days of the intervention protocol), only in case side effects or adverse events have been reported in the Safety Questionnaire. |
| Measure | Description | Time Frame |
|---|---|---|
| Computerized Cognitive Assessment | Complete cognitive evaluation based on Cognitive Assessment Battery (CogniFit Inc., San Francisco, USA). | In Phase II, at pre-test (the day before the intervention protocol starts) and at post-test (the day after the intervention protocol finishes). |
| Quality of Life Assessment |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Jon Andoni Duñabeitia, PhD | Contact | 0034 900321322 | jdunabeitia@nebrija.es | |
| David Asensio | Contact | dasensiob@alumnos.nebrija.es |
| Name | Affiliation | Role |
|---|---|---|
| Jon Andoni Duñabeitia, PhD | Universidad Nebrija | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Universidad Nebrija | Madrid | Spain |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000094024 | Post-Acute COVID-19 Syndrome |
| D060825 | Cognitive Dysfunction |
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
Not provided
Not provided
Phase I: An open-label prospective Phase I dose-escalation study following a standard 3+3 rule-based up-and-down design without dose de-escalation will be followed.
Phase II: An open-label prospective clinical trial to validate the minimum dosage and appropriate safety using the training time obtained in Phase I for the CCT along a 15-day training period with a 24-hour rest between sessions.
Not provided
Not provided
Not provided
Not provided
|
|
Short version of the self-perceived global physical and mental health scale from the Patient-Reported Outcomes Measurement Information System (PROMIS v.1.2). |
| In Phase II, at pre-test (the day before the intervention protocol starts) and at post-test (the day after the intervention protocol finishes). |
| Paper-and-pencil Cognitive Assessment | The Montreal Cognitive Assessment (MoCA). | In Phase II, at pre-test (the day before the intervention protocol starts) and at post-test (the day after the intervention protocol finishes). |
| D007239 |
| Infections |
| D014777 | Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D000094025 | Post-Infectious Disorders |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D003072 | Cognition Disorders |
| D019965 | Neurocognitive Disorders |
| D001523 | Mental Disorders |